On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the ...
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three ...
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: ...
Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new drug application (NDA) of tolebrutinib, an oral and ...
GSK plc announced plans to invest $30 billion in U.S. research and manufacturing over the next five years and entered a $500 ...
In the three years since a leadership change, Teva has evolved its R&D approach beyond a long history making copycat medicines.
GSK’s depemokimab shows strong potential for United States Food and Drug Administration approval in asthma and chronic ...
Roche's entry into the category with afimkibart (RG6631) stemmed from its purchase of Telavant for $7.1 billion, and since ...
Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback